EGFR and glioblastoma: Despite exhibiting promising efficacy against both wildtype EGFR and EGFRvIII in cell lines and patient-derived xenografts [53], ABT-414 did not confer survival benefits in newly diagnosed or recurrent GBM patients in the INTELLANCE 2 trial [54, 55].